Application of pharmacogenomics (PGx) in pediatrics is limited by interpretation frameworks developed for adults that do not account for ontogenetic changes in the activity of drug‑metabolizing enzymes and transport proteins. This study analyzed whole‑exome sequencing (WES) data from Russian pediatric patients and newborns to assess clinical applicability of PGx annotations, measure concordance between genotype‑based recommendations and developmental enzyme status, and develop age‑oriented reporting recommendations.
The cohort comprised 1,159 individuals: 524 pediatric patients and 635 newborns. WES data were analyzed and pharmacogenomic annotations filtered according to PharmGKB/ClinPGx evidence levels 1A through 2B and by the presence of a 'Pediatrics' tag. The authors assessed concordance between genotype‑based recommendations and the ontogenetic status of drug‑metabolizing enzymes specifically in the newborn cohort.
A retrospective review of medical records was performed in a pediatric subgroup of 100 patients to evaluate the structure of pharmacotherapy and frequency of adverse drug reactions (ADRs). The team created a 'PGx–ADR–cost' database and calculated a relative population burden index for 27 gene–variant–drug–ADR associations to prioritize clinically impactful pairs.
Ethics approval was obtained from the Local Research Ethics Committee of Russian National Medical University (Protocol No. 241, 26 June 2024), and participants provided written informed consent. Individual‑level sequencing data are restricted by national regulations and are available on reasonable request subject to institutional review board approval and compliance with legal and ethical requirements.
After filtering WES PGx annotations by evidence levels and pediatric tagging, clinically relevant annotations—defined as those requiring drug avoidance or dose modification—comprised only 5% of all initial pharmacogenomic annotations in both the pediatric and neonatal cohorts.
Within that clinically relevant subset, alleles associated with altered function made up 67.6% in the pediatric cohort and 67.2% in the neonatal cohort.
Concordance analysis in newborns demonstrated alignment between genotype‑based recommendations and ontogenetic enzyme status in only 5 of 14 (35.71%) gene–drug pairs evaluated, indicating frequent discordance when adult‑oriented PGx guidance is applied without developmental adjustment.
In the pediatric subgroup of 100 patients whose medical records were reviewed, ADRs were identified in 21% of patients. However, only two of these ADR cases could be explained by high‑evidence PharmGKB/ClinPGx annotations, suggesting limited explanatory power of current high‑evidence PGx annotations for ADRs observed in routine pediatric care when ontogenetic factors are not integrated.
The retrospective analysis also characterized the structure of pharmacotherapy in the subgroup, but the source did not provide further numerical breakdown of drug classes or prescribing patterns beyond ADR frequency and the proportion explained by high‑evidence annotations.
A 'PGx–ADR–cost' database was assembled and used to compute a relative population burden index across 27 gene–variant–drug–ADR associations. Ranking by this index identified priority associations for clinical attention in this population. The highest‑ranked associations reported were UGT1A1*28–irinotecan‑induced neutropenia and HLA‑A*31:01–carbamazepine‑induced severe cutaneous reactions. The source reported these as priority associations but did not provide full numerical burden index values in the abstract.
The study explicitly assessed concordance between genotype‑based PGx recommendations and the ontogenetic status of drug‑metabolizing enzymes in newborns. Concordance was present for 5 out of 14 gene–drug pairs (35.71%), indicating that in the majority of evaluated pairs, genotype‑only recommendations may not be appropriate for neonates without consideration of developmental enzyme expression and function. The source lists the concordance result but does not enumerate all 14 pairs or the specific pairs with concordance in the abstract.
Based on the observed limitations of adult‑derived PGx interpretation in pediatric contexts, the authors propose a pediatric PGx interpretation model with the following core elements:
Mandatory reporting of patient age on PGx reports to permit developmental interpretation.
Ontogenetic adjustment of genotype‑based recommendations to reflect age‑dependent enzyme and transporter activity.
Stratification of PGx annotations by evidence level to prioritize high‑certainty guidance.
Multidisciplinary clinical assessment to contextualize PGx findings within the patient’s clinical status, concomitant medications, and developmental stage.
The authors state that prospective validation is required to confirm the clinical utility of this proposed age‑aware approach.
Individual‑level DNA sequencing data are classified as sensitive under national regulations in the Russian Federation and are subject to legal and ethical restrictions. Access may be granted on reasonable request to the corresponding author, contingent on institutional review board approval and compliance with applicable legal and ethical requirements. The abstract does not provide more granular limitations such as specific variant frequencies, a full list of evaluated gene–drug pairs, or detailed numeric results for the 'PGx–ADR–cost' ranking beyond the top associations.
Competing interests were declared as none by the authors.
This WES‑based evaluation of pediatric PGx in 1,159 Russian children and newborns highlights that age and ontogeny are critical determinants of the clinical applicability of genotype‑based drug guidance. Clinically actionable PGx annotations were uncommon, and concordance between genotype recommendations and newborn enzyme maturation was low. The authors recommend an age‑aware PGx interpretation framework that mandates reporting of patient age, integrates ontogenetic adjustment, applies evidence‑level stratification, and uses multidisciplinary clinical review. They call for prospective studies to validate whether the proposed model improves prediction of ADRs and optimizes pediatric pharmacotherapy.